| Year |
Citation |
Score |
| 2020 |
Schech A, Brodie A, Lewis J, Tkaczuk K, Edelman MJ, Tait N, Chumsri S, Bao T, Stearns V. Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib Computers & Operations Research. 2020: 1-12. DOI: 10.31487/J.Cor.2020.07.04 |
0.773 |
|
| 2018 |
Khatri R, Shah P, Guha R, Rassool FV, Tomkinson AE, Brodie A, Jaiswal AK. Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Molecular Cancer Therapeutics. 17: 2491. PMID 30389813 DOI: 10.1158/1535-7163.MCT-17-0310 |
0.494 |
|
| 2017 |
Sabnis GJ, Kazi A, Schech A, Yu S, Golubeva O, Brodie A. Abstract 3604: Effect of a new oral SERD AZD9496 on ER mediated signaling in xenograft model of postmenopausal breast cancer Endocrinology. 77: 3604-3604. DOI: 10.1158/1538-7445.Am2017-3604 |
0.784 |
|
| 2016 |
Merchenthaler I, Lane M, Sabnis G, Brodie A, Nguyen V, Prokai L, Prokai-Tatrai K. Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes without hormonal effects in the periphery. Scientific Reports. 6: 30721. PMID 27477453 DOI: 10.1038/Srep30721 |
0.398 |
|
| 2016 |
Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YM, Zhou XC, Zhang Z, Connolly R, Stearns V, Ali SZ, Adams C, Chen Q, ... ... Brodie A, et al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Cancer Research. PMID 26787836 DOI: 10.1158/0008-5472.Can-15-1619 |
0.555 |
|
| 2015 |
Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, Kazi AA, Brodie A, MacBeath G. Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Molecular Cancer Therapeutics. PMID 26310543 DOI: 10.1158/1535-7163.Mct-15-0169 |
0.632 |
|
| 2015 |
Prokai L, Nguyen V, Szarka S, Garg P, Sabnis G, Bimonte-Nelson HA, McLaughlin KJ, Talboom JS, Conrad CD, Shughrue PJ, Gould TD, Brodie A, Merchenthaler I, Koulen P, Prokai-Tatrai K. The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders. Science Translational Medicine. 7: 297ra113. PMID 26203081 DOI: 10.1126/Scitranslmed.Aab1290 |
0.323 |
|
| 2015 |
Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment. PMID 26133921 DOI: 10.1007/S10549-015-3442-Z |
0.802 |
|
| 2015 |
Khatri R, Shah P, Guha R, Rassool FV, Tomkinson AE, Brodie A, Jaiswal AK. Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Molecular Cancer Therapeutics. 14: 1728-37. PMID 25976679 DOI: 10.1158/1535-7163.Mct-14-0672 |
0.533 |
|
| 2015 |
Brodie A, Russo J, Pasqualini JR. Hormones in normal and cancerous breast: basic and clinical applications. Hormone Molecular Biology and Clinical Investigation. 9: 1. PMID 25961349 DOI: 10.1515/Hmbci-2012-0021 |
0.474 |
|
| 2015 |
Schech A, Yu S, Shah P, Goloubeva O, Brodie A, Chumsri S, Sabnis G. Abstract P3-05-06: A nude mouse model of diet-induced-obesity to study the mechanisms of resistance to aromatase inhibitor letrozole in MCF-7Ca xenografts Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-06 |
0.767 |
|
| 2014 |
Chumsri S, Brodie A. Aromatase inhibitors and breast cancer. Hormone Molecular Biology and Clinical Investigation. 9: 119-26. PMID 25436703 DOI: 10.1515/hmbci-2012-0001 |
0.495 |
|
| 2014 |
Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncology (London, England). 10: 443-56. PMID 24559450 DOI: 10.2217/Fon.13.178 |
0.554 |
|
| 2014 |
Chumsri S, Schech A, Chakkabat C, Sabnis G, Brodie A. Advances in mechanisms of resistance to aromatase inhibitors. Expert Review of Anticancer Therapy. 14: 381-93. PMID 24559291 DOI: 10.1586/14737140.2014.882233 |
0.762 |
|
| 2014 |
Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Research : Bcr. 16: R15. PMID 24472707 DOI: 10.1186/Bcr3609 |
0.811 |
|
| 2014 |
Sabnis GJ, Goloubeva O, Shah P, Chumsri S, Brodie A. Abstract 621: Effect of diet-induced obesity on MCF-7Ca xenografts grown in ovariectomized athymic nude mice Cancer Research. 74: 621-621. DOI: 10.1158/1538-7445.Am2014-621 |
0.484 |
|
| 2014 |
Kazi AA, Sabnis G, Zhou Q, Chumsri S, Schech A, Shah P, Brodie A. Abstract 1471: HER2 regulated miRNA expression in letrozole resistant breast cancer Cancer Research. 74: 1471-1471. DOI: 10.1158/1538-7445.Am2014-1471 |
0.77 |
|
| 2013 |
Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Molecular Cancer Therapeutics. 12: 2804-16. PMID 24092810 DOI: 10.1158/1535-7163.MCT-13-0345 |
0.433 |
|
| 2013 |
Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Molecular Cancer Therapeutics. 12: 1356-66. PMID 23619300 DOI: 10.1158/1535-7163.Mct-12-0304 |
0.767 |
|
| 2013 |
Sabnis GJ, Kazi A, Golubeva O, Shah P, Brodie A. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Research and Treatment. 138: 699-708. PMID 23508762 DOI: 10.1007/S10549-013-2474-5 |
0.544 |
|
| 2013 |
Kazi AA, Shah P, Schech A, Sabnis G, Chumsri S, Brodie A. Abstract 95: Inhibiiton of non-hypoxic HIF-1 expression in letrozole-resistant breast cancer cells reduces their cancer stem cell characteristics. Cancer Research. 73: 95-95. DOI: 10.1158/1538-7445.Am2013-95 |
0.816 |
|
| 2013 |
Nagaria PK, Chowdhury K, Brodie A, Rassool F. Abstract 1778: C-MYC plays a novel role in driving the error-prone double-strand break repair in triple negative breast cancers. Cancer Research. 73: 1778-1778. DOI: 10.1158/1538-7445.Am2013-1778 |
0.428 |
|
| 2013 |
Sabnis GJ, Kazi A, Goloubeva O, Chumsri S, Brodie A. Abstract 1314: HDAC inhibitor entinostat reverses letrozole resistance in MCF-7Ca xenografts through modulation of Her-2. Cancer Research. 73: 1314-1314. DOI: 10.1158/1538-7445.Am2013-1314 |
0.542 |
|
| 2013 |
Shah P, Sabnis GJ, Goloubeva O, Kazi A, Schech A, Gilani R, Gau Y, Chumsri S, Brodie A. Abstract 1311: Preclinical assessment of an HDAC inhibitor combined with a retinoid in AI resistant breast cancer. Cancer Research. 73: 1311-1311. DOI: 10.1158/1538-7445.Am2013-1311 |
0.823 |
|
| 2013 |
Curley MD, Sabnis G, Wille L, Garcia G, Moyo V, Kazi A, MacBeath G, Brodie A. Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model. Cancer Research. 73: 1072-1072. DOI: 10.1158/1538-7445.Am2013-1072 |
0.634 |
|
| 2012 |
Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment. 135: 681-92. PMID 22878889 DOI: 10.1007/S10549-012-2148-8 |
0.824 |
|
| 2012 |
Schech AJ, Nemieboka BE, Brodie AH. Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction. The Journal of Steroid Biochemistry and Molecular Biology. 132: 195-202. PMID 22659283 DOI: 10.1016/J.Jsbmb.2012.05.008 |
0.782 |
|
| 2012 |
Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, Greco GE, Brodie AH, Tomkinson AE, Rassool FV. Targeting abnormal DNA repair in therapy-resistant breast cancers. Molecular Cancer Research : McR. 10: 96-107. PMID 22112941 DOI: 10.1158/1541-7786.MCR-11-0255 |
0.425 |
|
| 2012 |
Gilani R, Kazi AA, Scheh A, Chumsri S, Shah P, Brodie A. Abstract 787: Involvement of HER2, HIF-1, and BCRP in cancer stem cell characteristics of letrozole-resistant breast cancer cells Cancer Research. 72: 787-787. DOI: 10.1158/1538-7445.Am2012-787 |
0.819 |
|
| 2012 |
Sabnis GJ, Kazi A, Goloubeva O, Schech A, Shah P, Zhang B, Brodie A. Abstract 2919: Effect of selumetinib and AZD8055 on the growth of anastrozole resistant tumors Cancer Research. 72: 2919-2919. DOI: 10.1158/1538-7445.Am2012-2919 |
0.791 |
|
| 2011 |
Haluska P, Dhar A, Hou X, Huang F, Nuyten DS, Park J, Brodie AH, Ingle JN, Carboni JM, Gottardis MM, Wolff AC, Finckenstein FG. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS111. PMID 28022843 DOI: 10.1200/jco.2011.29.15_suppl.tps111 |
0.452 |
|
| 2011 |
Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM, Haluska P. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Research. 71: 7597-607. PMID 22042792 DOI: 10.1158/0008-5472.Can-11-1080 |
0.57 |
|
| 2011 |
Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. Bmc Cancer. 11: 231. PMID 21658239 DOI: 10.1186/1471-2407-11-231 |
0.605 |
|
| 2011 |
Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4208-13. PMID 21415222 DOI: 10.1158/1078-0432.Ccr-10-2920 |
0.584 |
|
| 2011 |
Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 125: 13-22. PMID 21335088 DOI: 10.1016/J.Jsbmb.2011.02.001 |
0.611 |
|
| 2011 |
Sabnis G, Brodie A. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Molecular and Cellular Endocrinology. 340: 142-7. PMID 20849912 DOI: 10.1016/J.Mce.2010.09.005 |
0.609 |
|
| 2011 |
Tobin LA, Chumsri S, Staats P, Brodie A, Tomkinson A, Rassool F. Abstract 5495: ALT NHEJ is a therapeutic target in hormone therapy resistant ER/PR/HER+ and ER/PR/HER- breast cancers Cancer Research. 71: 5495-5495. DOI: 10.1158/1538-7445.Am2011-5495 |
0.55 |
|
| 2011 |
Lee JH, Sabnis G, Brodie A, Nan A. Abstract 3230: In vitro evaluation of Her2 targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates in combination treatment with tyrosine kinase inhibitor (PKI-166) Cancer Research. 71: 3230-3230. DOI: 10.1158/1538-7445.Am2011-3230 |
0.506 |
|
| 2011 |
Sabnis GJ, Kazi A, Brodie A. Abstract 2295: Regulation of Her-2 in long-term letrozole resistant cells by HSP-90 Cancer Research. 71: 2295-2295. DOI: 10.1158/1538-7445.Am2011-2295 |
0.481 |
|
| 2011 |
Kochel T, Kundu N, Ma X, Reader J, Brodie A, Fulton AM. Abstract 1472: MRP4 and PGT, members of the COX-2 pathway, may contribute to breast cancer progression Cancer Research. 71: 1472-1472. DOI: 10.1158/1538-7445.Am2011-1472 |
0.568 |
|
| 2011 |
Goetz M, Hou X, Suman V, Reinicke K, Kuffel M, Haluska P, Oberg A, Grill D, Reid J, Brodie A, Ingle J, Ames M. PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd01-06 |
0.414 |
|
| 2011 |
Chumsri S, Brodie A. Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance Current Breast Cancer Reports. 3: 181-189. DOI: 10.1007/S12609-011-0056-2 |
0.554 |
|
| 2010 |
Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. British Journal of Cancer. 102: 815-26. PMID 20145614 DOI: 10.1038/sj.bjc.6605553 |
0.377 |
|
| 2010 |
Sabnis G, Brodie A. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clinical Breast Cancer. 10: E6-E15. PMID 20133251 DOI: 10.3816/Cbc.2010.N.014 |
0.596 |
|
| 2010 |
Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Molecular Cancer Therapeutics. 9: 46-56. PMID 20053764 DOI: 10.1158/1535-7163.Mct-09-0696 |
0.777 |
|
| 2010 |
Brodie A, Macedo L, Sabnis G. Aromatase resistance mechanisms in model systems in vivo. The Journal of Steroid Biochemistry and Molecular Biology. 118: 283-7. PMID 19778610 DOI: 10.1016/j.jsbmb.2009.09.004 |
0.492 |
|
| 2010 |
Nguyen NK, Korangath P, Sabnis G, Brodie A, Ordentlich P, Stearns V, Sukumar S. Abstract 5593: A combination of HDAC inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and low dose Doxorubicin causes regression of established xenografts of triple negative breast cancer Cancer Research. 70: 5593-5593. DOI: 10.1158/1538-7445.Am10-5593 |
0.563 |
|
| 2010 |
Molitoris KH, Brodie A, Koos RD. Abstract 4596: Restoring hypoxia-inducible factor-1α in MCF-7 breast cancer cells in vitro by preventing the excessive degradation induced by high oxygen unmasks strong estradiol induction of vascular endothelial growth factor expression Cancer Research. 70: 4596-4596. DOI: 10.1158/1538-7445.Am10-4596 |
0.42 |
|
| 2009 |
Smollich M, Götte M, Fischgräbe J, Macedo LF, Brodie A, Chen S, Radke I, Kiesel L, Wülfing P. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Research and Treatment. 123: 345-57. PMID 19943105 DOI: 10.1007/s10549-009-0644-2 |
0.506 |
|
| 2009 |
Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target Endocrine Reviews. 30: 343-375. PMID 19389994 DOI: 10.1210/Er.2008-0016 |
0.513 |
|
| 2009 |
Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Annals of the New York Academy of Sciences. 1155: 162-73. PMID 19250202 DOI: 10.1111/J.1749-6632.2008.03689.X |
0.616 |
|
| 2009 |
Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Research. 69: 1416-28. PMID 19190349 DOI: 10.1158/0008-5472.Can-08-0857 |
0.827 |
|
| 2009 |
Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urologic Oncology. 27: 53-63. PMID 19111799 DOI: 10.1016/J.Urolonc.2008.07.036 |
0.786 |
|
| 2008 |
Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Research. 68: 3516-22. PMID 18451180 DOI: 10.1158/0008-5472.Can-07-6807 |
0.602 |
|
| 2008 |
Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer. 112: 679-88. PMID 18072255 DOI: 10.1002/Cncr.23191 |
0.593 |
|
| 2008 |
Sabnis GJ, Macedo L, Goloubeva O, Schayowitz A, Zhu Y, Brodie A. Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. The Journal of Steroid Biochemistry and Molecular Biology. 108: 1-7. PMID 17942301 DOI: 10.1016/J.Jsbmb.2007.04.005 |
0.816 |
|
| 2007 |
Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2751-7. PMID 17473209 DOI: 10.1158/1078-0432.Ccr-06-2466 |
0.829 |
|
| 2006 |
Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ, Borowsky AD, Kung HJ, Wei G, Ostrowski MC, Brodie A, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Research. 66: 8058-64. PMID 16912182 DOI: 10.1158/0008-5472.Can-06-1364 |
0.332 |
|
| 2006 |
Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Research. 66: 7775-82. PMID 16885381 DOI: 10.1158/0008-5472.Can-05-3984 |
0.579 |
|
| 2006 |
Brodie A. David Kupfer and the Metabolism Connection: On Aromatase Inhibitors and Tamoxifen Drug Metabolism Reviews. 38: 129-137. PMID 16684652 DOI: 10.1080/03602530600569901 |
0.484 |
|
| 2005 |
Macpherson N, Moore S, Brodie A, Thiantanawat A, Jelovac D, Nelson CC. Gene expression changes during acquired resistance to tamoxifen and letrozole; a preclinical model of post-menopausal breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9620. PMID 27943756 DOI: 10.1200/Jco.2005.23.16_Suppl.9620 |
0.544 |
|
| 2005 |
Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 9890-5. PMID 15994225 DOI: 10.1073/Pnas.0503829102 |
0.392 |
|
| 2005 |
Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. The Journal of Steroid Biochemistry and Molecular Biology. 95: 41-8. PMID 15967659 DOI: 10.1016/J.Jsbmb.2005.04.026 |
0.573 |
|
| 2005 |
Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Research. 65: 3903-10. PMID 15867390 DOI: 10.1158/0008-5472.Can-04-4092 |
0.527 |
|
| 2005 |
Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O, Osborne K, Santen R, Johnston S, Yee D, Lønning P, Ingle J. Therapeutic observations in MCF-7 aromatase xenografts Clinical Cancer Research. 11. PMID 15701882 |
0.436 |
|
| 2005 |
Núñez NP, Jelovac D, Macedo L, Berrigan D, Perkins SN, Hursting SD, Barrett JC, Brodie A. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5375-80. PMID 15328175 DOI: 10.1158/1078-0432.Ccr-04-0261 |
0.484 |
|
| 2004 |
Macpherson N, Moore S, Brodie A, Olivotto T, Thiantanawat A, Long B, Jelovac D, Nelson C. Gene expression changes during acquired resistance to tamoxifen; a preclinical model of post-menopausal breast cancer Journal of Clinical Oncology. 22: 3147-3147. DOI: 10.1200/Jco.2004.22.90140.3147 |
0.62 |
|
| 2003 |
Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the endocrine management of breast cancer. Breast (Edinburgh, Scotland). 12: S2-19. PMID 14659138 DOI: 10.1016/S0960-9776(03)80158-3 |
0.468 |
|
| 2003 |
Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. The Journal of Steroid Biochemistry and Molecular Biology. 86: 283-8. PMID 14623522 DOI: 10.1016/S0960-0760(03)00368-6 |
0.439 |
|
| 2003 |
Brodie A. Aromatase inhibitor development and hormone therapy: a perspective. Seminars in Oncology. 30: 12-22. PMID 14513433 DOI: 10.1016/s0093-7754(03)00303-8 |
0.46 |
|
| 2003 |
Brodie AH, Mouridsen HT. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. American Journal of Clinical Oncology. 26: S17-26. PMID 12902873 DOI: 10.1097/00000421-200308001-00004 |
0.438 |
|
| 2003 |
Brodie A, Jelovac D, Long BJ. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 455S-9S. PMID 12538500 |
0.508 |
|
| 2003 |
Brodie AH, Jelovac D, Long B. Treatment Strategies Using Letrozole and Tamoxifen in a Xenograft Model for Breast Cancer American Journal of Cancer. 2: 1-6. DOI: 10.2165/00024669-200302001-00001 |
0.419 |
|
| 2003 |
Brodie AH, Jelovac D, Long B. Treatment strategies using letrozole and tamoxifen in a xenograft model for breast cancer: Combined treatment versus alternating or sequential treatment American Journal of Cancer. 2: 1-6. |
0.544 |
|
| 2002 |
Brodie A. Aromatase inhibitors in breast cancer. Trends in Endocrinology and Metabolism. 13: 61-65. PMID 11854020 DOI: 10.1016/S1043-2760(01)00529-X |
0.538 |
|
| 2001 |
Brodie A, Inkster S, Yue W. Aromatase expression in the human male. Molecular and Cellular Endocrinology. 178: 23-28. PMID 11403890 DOI: 10.1016/S0303-7207(01)00444-0 |
0.367 |
|
| 2000 |
Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocrine-Related Cancer. 6: 205-10. PMID 10731110 DOI: 10.1677/erc.0.0060205 |
0.551 |
|
| 2000 |
Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Research and Treatment. 57: 183-92. PMID 10598045 DOI: 10.1023/A:1006225601046 |
0.58 |
|
| 1999 |
Lu Q, Yue W, Wang J, Liu Y, Long B, Brodie A. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Research and Treatment. 50: 63-71. PMID 9802621 DOI: 10.1023/A:1006004930930 |
0.498 |
|
| 1998 |
Brodie A, Long B, Lu Q. Aromatase expression in the human breast Breast Cancer Research and Treatment. 49. PMID 9797022 DOI: 10.1023/A:1006029612990 |
0.539 |
|
| 1998 |
Brodie A, Lu Q, Yue W, Wang J, Liu Y. Intratumoral aromatase model: the effects of letrozole (CGS 20267). Breast Cancer Research and Treatment. S23-6; discussion S3. PMID 9797014 DOI: 10.1023/A:1006028202087 |
0.602 |
|
| 1997 |
Brodie A, Lu Q, Nakamura J. Aromatase in the normal breast and breast cancer The Journal of Steroid Biochemistry and Molecular Biology. 61: 281-286. DOI: 10.1016/S0960-0760(97)80024-6 |
0.566 |
|
| 1996 |
Nakamura J, Savinov A, Lu Q, Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors Endocrinology. 137: 5589-5596. PMID 8940388 DOI: 10.1210/Endo.137.12.8940388 |
0.37 |
|
| 1996 |
Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology. 137: 3061-3068. PMID 8770932 DOI: 10.1210/Endo.137.7.8770932 |
0.522 |
|
| 1995 |
Zhou J, Brodie A. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat. The Journal of Steroid Biochemistry and Molecular Biology. 52: 71-76. PMID 7857875 DOI: 10.1016/0960-0760(94)00145-C |
0.438 |
|
| 1995 |
Inkster S, Yue W, Brodie A. Human testicular aromatase: Immunocytochemical and biochemical studies Journal of Clinical Endocrinology and Metabolism. 80: 1941-1947. PMID 7539819 DOI: 10.1210/Jcem.80.6.7539819 |
0.322 |
|
| 1993 |
Yue W, Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors Journal of Steroid Biochemistry and Molecular Biology. 44: 671-673. PMID 8476781 DOI: 10.1016/0960-0760(93)90278-5 |
0.511 |
|
| 1993 |
Brodie A, Inkster S. Aromatase in the human testis The Journal of Steroid Biochemistry and Molecular Biology. 44: 549-555. PMID 8476768 DOI: 10.1016/0960-0760(93)90258-X |
0.352 |
|
| 1991 |
Brodie A. Aromatase inhibitors: introduction and perspective. Journal of Enzyme Inhibition. 4: 75-7. PMID 2098525 DOI: 10.3109/14756369009040729 |
0.325 |
|
| 1991 |
Coen P, Kulin H, Ballantine T, Zaino R, Frauenhoffer E, Boal D, Inkster S, Brodie A, Santen R. An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. The New England Journal of Medicine. 324: 317-22. PMID 1986290 DOI: 10.1056/Nejm199101313240507 |
0.352 |
|
| 1984 |
Coombes RC, Dowsett M, Goss P, Gazet J, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. The Lancet. 324: 1237-1239. PMID 6150277 DOI: 10.1016/S0140-6736(84)92795-8 |
0.491 |
|
| 1983 |
Billig H, Hillensjö T, Tsafriri A, Mangusson C, Brodie A. Nuclear maturation of follicle-enclosed rat oocytes during inhibition of steriodogenesis Gamete Research. 8: 79-86. DOI: 10.1002/Mrd.1120080109 |
0.314 |
|
| Show low-probability matches. |